The Balancing Act® on Lifetime to Feature ENPP1 Deficiency
Educational Episode to Highlight Symptoms of ENPP1 Deficiency and the Importance of Early Diagnosis
BOSTON, March 11, 2021 (GLOBE NEWSWIRE) Inozyme Pharma, Inc., a rare disease biopharmaceutical company developing novel therapeutics for the treatment of disorders of abnormal mineralization, announced today that ENPP1 deficiency will be featured on The Balancing Act
® as part of the show’s recurring “Behind the Mystery of Rare and Genetic Diseases” series to raise awareness for this rare, debilitating, and life-threatening mineralization disease for which there are currently no approved treatment options.
The episode will feature Janine Hicks, a patient living with ENPP1 deficiency; her parents, Donna and Peter Hicks; and Professor Zulf Mughal, a treating physician and researcher and Consultant in Pediatric Bone Disorders, Royal Manchester Children’s Hospital, Manchester University NHS Foundation Trust. The se